• To examine the efficacy of the monoamine oxidase inhibitor phenelzine sulfate in the treatment of bulimia, a doubleblind, placebo-controlled trial was conducted. In 50 women who completed the trial, phenelzine was significantly superior to placebo in the reduction of binge frequency (64% vs 5%), in the fraction of patients who had ceased bingeing at the end of the trial (35% vs 4%), and in several measures of psychological state. The superiority of phenelzine over placebo was not confined to a depressed subgroup of patients. Although no patient experienced a hypertensive crisis during the study, other side effects of phenelzine were problematic and limit the usefulness of phenelzine in this population.
Walsh BT, Gladis M, Roose SP, Stewart JW, Stetner F, Glassman AH. Phenelzine vs Placebo in 50 Patients With Bulimia. Arch Gen Psychiatry. 1988;45(5):471–475. doi:10.1001/archpsyc.1988.01800290091011
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.